IBO (Impact BioMedical) Debt-to-Asset : 0.17 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Impact BioMedical Debt-to-Asset?

Impact BioMedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.04 Mil. Impact BioMedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $7.97 Mil. Impact BioMedical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $46.70 Mil. Impact BioMedical's debt to asset for the quarter that ended in Sep. 2024 was 0.17.

Impact BioMedical Debt-to-Asset Historical Data

The historical data trend for Impact BioMedical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impact BioMedical Debt-to-Asset Chart

Impact BioMedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.02

0.22

0.27

Impact BioMedical Quarterly Data
	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.26	0.27	0.29	0.31	0.17

Competitive Comparison of Impact BioMedical's Debt-to-Asset

For the Biotechnology subindustry, Impact BioMedical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impact BioMedical's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impact BioMedical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Impact BioMedical's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Impact BioMedical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Impact BioMedical's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(12.074	+	0)	/	44.633
	=	0.27

Impact BioMedical's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.035	+	7.971)	/	46.695
	=	0.17

Impact BioMedical (AMEX:IBO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Impact BioMedical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Impact BioMedical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Impact BioMedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impact BioMedical Inc (AMEX:IBO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wiregrass Parkway, West Henrietta, NY, USA, 14586

Website

https://www.impactbiomedinc.com

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Impact BioMedical Headlines

From GuruFocus

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

By Marketwired • 09-16-2024